Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report
Matthew Siskin, Joshua K. Sabari
Current Problems in Cancer: Case Reports · 2022
doi:10.1016/j.cpccr.2022.100171 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
An 83-year-old woman presents with two synchronous primary lung adenocarcinomas each harboring unique EGFR mutations, one classical and the other rare. She was treated with adjuvant Osimertinib following surgical lobectomy and remains well 44 months from the time of her diagnosis. Her case demonstrates the potential value in using EGFR third generation TKI monotherapy in patients with early-stage disease, harboring rare mutations and in patients with multiple primary cancers harboring targetable mutations. Further research into the use of targeted therapy in these areas is needed.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.